Pursuits
Merck to Submit Ebola Vaccine for Approval by End of 2017
- Merck to provide 300,000 doses of vaccine starting in May
- Vaccine to be made available for more trials, emergency use
A Transmission Electron Micrograph (TEM) of the Ebola virus.
Source: Murphy/CDC via Getty ImagesThis article is for subscribers only.
Merck & Co. has signed an agreement with Gavi, the world’s biggest funder of vaccines for developing countries, to submit its experimental Ebola vaccine for regulatory approval by the end of 2017.
Gavi, which brings together funds from governments, companies, United Nations agencies and philanthropic groups like the Bill & Melinda Gates Foundation, committed $5 million to the development of the vaccine in an agreement announced at the World Economic Forum in Davos, Switzerland. Merck will also ensure that 300,000 vaccine doses are available starting in May for use in clinical trials and emergencies.